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Summary.-Walker carcinosarcoma cells cause in vitro osteolysis which may be
inhibited by aspirin. In the rat, this tumour produces osteolytic bone deposits and
hypercalcaemia, both of which can be prevented by aspirin and indomethacin,
whereas soft tissue tumour deposits are unaffected by these drugs. Some human
breast tumours cause in vitro osteolysis which may be inhibited by aspirin.
PATIENTS with breast cancer frequently
develop abnormalities in their calcium
metabolism, which are usually associated
with osteolytic bone metastases (Galasko
and Burn, 1971) and are caused by exces-
sive mobilization of calcium from the
skeleton. This raises the possibility that
the mechanism for this skeletal calcium
mobilization, and the ability of tumour
deposits to develop into destructive bone
deposits, may both depend on the ability
of tumour cells to produce osteolytic
substances.
To investigate this hypothesis, we have
used an in vitro organ culture system of
neonatal mouse bone which releases cal-
cium in response to known osteolytic
substances. We have found that some,
but not all, human breast carcinomata
when added to the organ culture caused
increased calcium release from the bones
and that this osteolysis could be inhibited
by aspirin.
To test whether these in vitro obser-
vations were relevant to the in vivo
behaviour of tumours, it was necessary to
develop a suitable animal tumour model.
For this, we chose the intra-aortic injec-
tion of Walker carcinosarcoma cells into
the rat, because this tumour has been
reported to cause hypercalcaemia (Raue
et al., 1972) and will give rise to lytic
bonedeposits. Wefoundthat thistumour
had in vitro osteolytic activity which could
be partly inhibited by aspirin, and we
have therefore used the in vivo model to
investigate the ability of agents such
as aspirin to inhibit tumour induced
osteolysis and hypercalcaemia.
MATERIALS AND METHODS
In vitro organ culture system. Two-day
old BALB/c mice were injected intraperi-
toneally with 1-2 ,tCi of 45CaCl2, and 2 days
later lightly anaesthetized with ether and
decapitated. Both frontoparietal bones were
dissected out and each bone cultured accord-
ing to the method of Reynolds (1968) on a
stainless steel grid in a plastic petri dish
containing 5 ml of Bigger's medium (BJGB,
Flow Laboratories) with 5%0 heat inactivated
rabbit serum (Burroughs Wellcome No. 1).
The bones were cultured in 5 0 CO2 in air at
37°C for a preliminary period of 24 hours
before being transferred to new dishes with
fresh medium, some of wA-hich contained sub-
stances or tumours under test.
These were cultured for a further 3 days
under the same conditions as for the prelimi-
naryperiod, during whichtime calcium passed
from the bone into the medium. At the end
of the culture period the 45Ca in the medium,
and remaining in the bone, was estimated
using a Packard scintillation counter. TheINHIBITION BY ASPIRIN OF TUMOUR DEPOSITS
percentage released from bones cultured in
medium containing test substances was
compared with that from bones cultured in
control medium.
Samples of human breast tumours were
collected at operation, transported in culture
medium andimmediately cutinto small pieces
1-2 mm in diameter. Four of these pieces
were introduced into the organ culture system
by placing them around the bone on the grid
at a distance of4-5 mm from the bone.
Suspensions of Walker tumour cells were
obtained from rats bearing the tumour in the
ascitic form by washing out the peritoneal
cavity with Hepes buffered medium 199.
Tumour aggregates and most erythrocytes
were removed by gentle centrifugation to
leave single cells in suspension, known num-
bers of which were finally suspended in
Bigger's medium and added to the petri
dishes.
Aspirin was introduced into the culture
system by dissolving pure acetyl salicylic acid
inBigger'smediumanddilutingtotherequired
concentration.
ThepH ofthemedium wasmeasured atthe
beginning and the end of the 3 day culture
period for all cultures.
In vivo animal tumour system.-In pre-
liminary experiments on rats we found that
intra-aortic injection of Walker tumour cells
resulted in the development of soft tissue and
lytic bone tumour deposits in the legs, and
also hypercalcaemia. To test whether anti-
osteolytic agents, effective in vitro, could
influence the development of destructive
bone deposits and hypercalcaemia, we per-
formed 3 experiments injecting 103 Walker
cells (as a single cell suspension in 0-2 ml of
medium 199) into the abdominal aorta of
120 g male Wistar rats. The animals in each
experiment were divided into 2 groups; a
test group in which the animals were force fed
daily with aspirin and indomethacin dis-
solved in water, and a control group force
fed with an equal volume of water. Most
of the pharmacological actions of aspirin are
similar to those of indomethacin, and there-
fore to test for any in vivo anti-osteolytic
activity by aspirin it was decided to use
aspirinwithindomethacinintheseexperiments
to achieve maximum aspirin-like effect.
In Experiments I and II the test animals
were given 30 mg of aspirin and 041 mg of
indomethacin per day, commencing 3 days
before tumour cell administration. After
10 days the drug dosages were doubled. In
Experiment III, the test animals were given
60 mg of aspirin and 0-2 mg of indomethacin
per day, commencing 7 days after tumour cell
administration.
The animals were sacrificed by decapita-
tion 14 days after tumour cell administration,
blood samples collected and the serum cal-
cium levels determined by the routine clinical
autoanalytical method. The extent of soft
tissue tumour was evaluated at post mortem
examination by weighing the legs and sub-
tracting the weights of legs from control
non-tumour bearing animals ofthe same body
weight. The number of osteolytic bone
deposits were evaluated by x-ray examina-
tion of the legs, the x-ray plates being coded
and assessed independently by 2 observers.
Obvious destructive bone deposits occurred
in the legs only at the lower end of the femur
and the upper end of the tibia and each bone
either had an obvious destructive lesion or
not, making a possible total number of bone
deposits for each animal of0, 1, 2, 3, or 4.
RESULTS
In vitro experiments
Some, but not all, human breast
tumours caused marked increases in the
release of 45Ca from the labelled bones in
culture. Three of these active tumours
were also tested for activity in the
presence of aspirin (16 ,ag/ml) and found
to be significantly inhibited by this drug
(Table I). The depression of pH of the
TABLE I.-45Ca Release from Neonatal
Mouse Bones Effected by Human
Mammary Carcinomata
% 45Calcium release in 3 days
Breast Control + Tumour+
tumour Control aspirin* Tumour aspirin*
D.M. 19 8i1*7 22*7±1i9 39*0±3-1 26 9±1 1
A.S. 11-7±004 12*7±i05 23-8±5i7 15*0±1*3
A.C. 14 4±0i7 14 8±0 9 32*7±1*1 20 6±2.0
* Aspirin 16 Ug/ml medium.
medium resulting from the presence of
the human tumours was small (about 01
pH unit) and was independent of the
presence or absence of aspirin.
Walker tumour cells at varying con-
centrations caused release of 45Ca from
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TABLE II.-45Ca Release from Neonatal
Mouse Bones Effected by Walker Tumour
Cells
No. of Walker
cells per
culture dish
0
1 x 106
2 x 106
4x 106
% 45Calcium release in 3 days
Medium+ Medium + aspirin*
Walker cells +Walker cells
16-6±1*61
28-6±2 4 22*1±1 3
40*0±+45 30 1±1*4
54*8±+20 49*1 ±1*9
TABLE III.-The Effect of pH on 45Ca
Releasefrom Neonatal Mouse Bones
Lactic acid conc.
of medium (mg/ml) pH of medium
0 7-53±002
0-65 7-41±0-04
0-96 7*31±002
1*30 7-25±0*03
1-63 7*15±0*04
1-95 6*98±0-01
* Aspirin-16 jsg/ml medium.
the bones in culture and aspirin (16 ,tg/ml)
significantly inhibited this release (Table
II). Indomethacin (2 jtg/ml) gave a simi-
lar inhibition of calcium release. This
concentration of aspirin appeared to have
no detectable effect on the metabolism
or viability ofthe tumour cells as assessed
by dye exclusion, phase contrast micro-
scopy and acid production.
Reduction of the pH of the medium
by the addition of lactic acid also pro-
duced increased 45Ca release (Table III),
U)
0
10
Cr
U.)
,0
L)
0 'fl
0
0
40O
30O
201
which was slightly inhibited by aspirin
(Table IV), and therefore acid production
by tumour cells must be taken into
account when evaluating the total osteo-
lytic effect of these cells in vitro. This
may be done by using a " correction "
curve for the pH effect of lactic acid and
comparingthiswiththe 45Carelease caused
by Walker cells in relation to the pH
change caused by the cells. For 2 concen-
trations of Walker cells this is represented
graphically in Fig. 1 and shows that the
osteolytic effect ofthese cells is in excess of
that expected by acid production alone,
A1
_-_-
_1 _ I I I I I
6-9 6-8
FIG. 1.-45Ca release from neontal mouse bones effected by Walker tumour cells in relation to the
release caused by lactic acid.
% 45Calcium
release
17-5±1-8
19 6±2*8
20-4±0 6
22*3±1*4
25*2±1*4
28 5±1 1
* 1 x 106 Cells
o X x 10' Cells + Aspirin
A 2 x 10' Cells
A 2 x 10' Cells+ Aspirin
74 73 7-2 7 1 7.0
pH medium at 3 days
_-A-% 501 7
-
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TABLE IV. The Effect of Aspirin on
Lactic Acid Induced 45Ca Release from
Neonatal Mouse Bones
Aledium
Medium+aspirin (16 jig/ml)
Medium+lactic acid
(1 4 mg/ml)
Medium+lactic acid (1 * 4
mg/ml) +aspirin (16
,ug/ml)
pH
meclitum
7-36
7-36
% 45Calcitum
release
15-8±1 *4
15- 7±I-4
6-98 26-6±1-7
6-98 23-1 1-0
TABLE V. The Effect of Aspirin and
Indomethacin on Walker Tumour in
Bones and Soft Tissues. and on Serum
Calcium Levels. Drug Administration
Started 3 Days before Tumour Cell
.Injection
Experiment I
No. of bone No. of animals
deposits per
A
animal Controls (8) Treated (8)
0 1 8
and that this excess may be significantly
inhibited by aspirin. It should be noted
that the pH correction is possibly exces-
sive because the pH is measured at the
end of the culture period and, although
this represents the pH for the whole
culture period when lactic acid is added at
the beginning of the culture, it does not
for tumour cells, which release acid
gradually throughout the culture period.
In vivo experinments
In Experiment I, 8 rats were treated
with aspirin and indomethacin and 8 rats
used as control. All animals in both
groups developed clinically obvious soft
tissue tumours in the legs on the 10th or
11th day after tumour cell injection, and
when all the animals were sacrificed on
the 14th day there was no significant
difference in the amount of soft tissue
tumours in the control and treated groups.
However, although all but one of the
control animals had obvious destructive
tumour deposits in the bones of the legs
and 2 animals were hypercalcaemic, none
of the treated animals had any detectable
bone deposits and none were hypercal-
caemic (Table V). In Experiment II,
comprising 21 animals, the tumours in
the soft tissues became clinically obvious
rather earlier than in Experiment I and
by Day 14, when the animals were sacri-
ficed, there was more soft tissue tumour.
Again, there was no significant inhibition
of growth of soft tissue tumour in the
treated compared with the control group.
However, although all the control group
2
3
4
Wt of soft tissue
tumour g/animal
Seium calcium
mg/100 ml
3
2
0
0
0
77-727 6 8±2 6
11 8-1 3 10 9±0-4
animals had widespread bone deposits,
none ofthe treated animals had detectable
bone deposits and the hypercalcaemia
which had developed in all but one of the
control animals was prevented in all the
treated animals (Table VI). In Experi-
ment III, in which administration of
TABLE VI. The Effect of Aspirin and
Indomethacin on Walker Tumour in
Bone and Soft Tissue, and on Serum,
Calcium Levels. Drug Administration
Started 3 Days before Tumour Cell
Injection
Experiinenit II
No. of bone
deposits per
animal
0
1
2
:3
4
Wt of soft tissue
tumour g/animal
Serum calcium
mg/100 ml
No. of animals
Controls (11) Treated (10)
o 10
0 0
1 0
0 0
10 0
8-9±3-8 116±4 4
14 2±1-4 11-0±0-6
aspirin and indomethacin did not com-
mence until 7 days after the tumour cell
injection, a similar result was obtained
with complete prevention of destructive
bone deposits in the treated group (Table
VII).
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TABLE VII.-The Effect of Aspirin and
Indomethacin on Walker Tumour in
Bones and Soft Tissue. Drug Adminis-
tration Started 7 Days after Tumour Cell
Injection
Experiment III
No. of bone
deposits per
animal
0
1
2
3
4
Wt of soft tissue
tumour g/animal
No. of animals
Controls (10) Treated (9)
0 9
2 0
0 0
2 0
6 0
12-9±2*7 16-4±2*7
DISCUSSION
We have shown that aspirin with
indomethacin is able to inhibit tumour
development in the bones but not in the
soft tissues of rats after injection of
Walker tumour cells into the aorta, and
that this occurs even when drug adminis-
tration commences one week after tumour
cell injection. This strongly indicates
that the inhibitory effect of these drugs
occurs after the tumour cells have left the
circulation and cannot be caused by
changes in platelet aggregation or tumour
cell distribution. The drugs do not signi-
ficantly affect the development of soft
tissue tumour, which suggests that they
do not possess general anti-tumour or
anti-metastatic properties in this system.
However, we have shown that these
drugs prevent hypercalcaemia developing
in the rats, and in vitro we have shown
that they are able to inhibit the osteolytic
effect of Walker cells on neonatal mouse
bones in organ cultures. This suggests
that these drugs might inhibit the in vivo
development of tumour in bone, and
hypercalcaemia, by inhibition of local
osteolysis by tumour deposits already in
the marrow.
How these anti-inflammatory agents
inhibit tumour induced osteolysis is un-
known. Poole (1970) has demonstrated
cartilage matrix degradation by lysosomal
enzymes associatedwith tumourimplanted
on the xiphisternum of the rat. Aspirin
is known to influence the function of
components of the lysosomal system, and
while it has apparently failed in some
systems to influence lysosomal membrane
stability (Weissmann, 1968) or to decrease
the release of lysosomal enzymes from
some types of intact cells (Wright and
Malawista, 1971), Miller and Smith (1966)
have shown that aspirin is able to cause
effective stabilization of rat liver lyso-
somes. Itisthereforepossiblethataspirin
is able to inhibit tumour induced osteo-
lysis in our in vitro and in vivo systems
either by inhibiting the release of osteo-
lytic lysosomal enzymes by the tumour
cells and/or by inhibiting the release of
these enzymes from the stimulated bone
cells. Osteolysis may also be influenced
by the local production ofacid by tumours
in bone. Gullino et al. (1965) have
measured the pH ofinterstitial fluid in the
Walker tumour and found it to be consis-
tently lower than comparable subcu-
taneous areas by about 0 4 units, a depres-
sion quite sufficient toproduce asignificant
increase in calcium release from bone in
the in vitro system. This, however, is
not substantially inhibited by aspirin and
we therefore conclude that although low
pH may facilitate the local action of
lysosomal enzymes, it is not the main
factor responsible for local osteolysis.
Another possible inhibitory mechanism
ofaspirin may involve its ability to inhibit
prostaglandin synthesis (Vane, 1971). Pro-
staglandins have been shown to cause in
vitro osteolysis (Kleinand Raisz, 1970) and
may also be responsible for the in vitro
osteolytic properties of a mouse fibro-
sarcoma (Tashjian et al., 1972). The
production of prostaglandin E2 and the
in vitro osteolysis caused by this tumour
were both inhibited by indomethacin.
It has been shown that some human
breast tumours possess in vitro osteolytic
properties which may be significantly
inhibited by aspirin, and it is possible
that the abnormalities in calcium meta-
bolism in patients with breast cancer may
depend on production of osteolytic sub-INHIBITION BY ASPIRIN OF TUMOUR DEPOSITS 321
stance by the tumour which may also
facilitate the growth ofmetastases in bone.
Aspirin may therefore be effective in the
prevention of hypercalcaemia and bone
metastases. Accordingly, we are cur-
rently evaluating the effect of aspirin on
the calcium metabolism of patients with
breast cancer and its influence on the
developmentofbone metastasesinpatients
whose primary tumours are osteolytically
active.
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